SREBP1C_FN_CTL · Characterising the role of mammalian Target Of Rapamcyin Complex 1 (mTORC1)/Srebp1c signaling in directing the differentiation and function of T lymphocytes
FP7 — People (Marie Curie Actions)
- Duration
- 2012-08-01 → 2016-07-31
- EU contribution
- €100,000
- Participants
- 1
- Scheme
- MC-CIG
Lines connect the coordinator with its partners.
Results in brief
Characterising the role of mammalian Target Of Rapamcyin Complex 1 (mTORC1)/Srebp1c signaling in directing the differentiation and function of T lymphocytes
The mammalian target of rapamcyin complex 1 (mTORC1) is a key regulator of cellular metabolism and also has fundamental roles in controlling immune responses. Emerging evidence suggests that these two functions of mTORC1 are integrally linked. However, little is known regarding mTORC1 function in controlling the metabolism and function of natural killer (NK) cells, lymphocytes that play key roles in anti-viral and anti-tumour immunity. This study investigated the hypothesis that mTORC1-controlled metabolism underpins normal NK cell pro-inflammatory function. We demonstrate that mTORC1 is robustly stimulated in NK cells activated in vivo and in vitro. This mTORC1 activity is required for the production of the key NK cell effector molecules IFNgamma, important in delivering antimicrobial and immunoregulatory functions, and granzyme B, a critical component of NK cell cytotoxic granules. The data reveal that NK cells undergo dramatic metabolic reprogramming upon activation, up-regulating rates of glucose uptake and glycolysis, and that mTORC1 activity is essential for attaining this elevated glycolytic state. Directly limiting the rate of glycolysis is sufficient to inhibit IFNgamma production and granzyme B expression. This study provides the highly novel insight that mTORC1-mediated metabolic reprogramming of NK cells is a prerequisite for the acquisition of normal effector functions. This work was published in Journal of Immunology in 2014 (PMID:25261477) Our on going work is currently further characterising the link between mTORC1 regulated NK cell metabolism and NK cells function and the elucidating molecular mechanisms involved. We have discovered key roles for cMyc and Srebp, but not HIF1alpha, in controlling NK cell glucose metabolism and function. These results are being compiled into 2 manuscripts that will be submitted for consideration at a high impact journals by the end of 2016. Another key objective of this CIG grant was to fully integrate into the research environment at Trinity College Dublin. This objective has been fully realized since the start of this grant. The CIG award has facilitated the establishment of a research group that included 7 PhD students and 1 postdoctoral research scientist. This has been achieved through securing additional funding from national funding agencies. I have published a number of research articles including 2 articles in the Journal of Immunology as senior and corresponding author. I have also been invited to write an number of review articles on the area of immunometabolism for high impact journals including the Journal of Clinical Investigation (5 review articles published, 2015-2016). Therefore, with the help of this Marie Curie Career integration grant I have successfully established a research group in Trinity College Dublin and this research is producing key outputs in the form of research articles in high impact and respected journals.
Data: CORDIS, © European Union
Project objective
Modulating immune responses by shifting the balance of effector versus regulatory/memory T cells has significant potential as therapy for various autoimmune diseases and preventing organ transplant rejection. The mammalian Target Of Rapamycin Complex 1 (mTORC1) has diverse effects in T cells and can function to direct T cell fate. Direct mTORC1 inhibition provides potent immunosuppression but is associated with significant toxicity. Dissecting the mechanisms that account for the multiple mTORC1 effects on T cell differentiation is required to develop targeted therapies that provide desirable immunomodulatory effects without the toxicity associated with rapamycin treatment.The function of activated T cells is closely linked to their elevated metabolic state. Thus, inhibition of T cell metabolism via disruption of glucose metabolism or amino acid availability can alter T cell function. mTORC1 activity is acutely sensitive to the metabolic cues and has established roles in regulating cellular metabolism in other systems, through the control of Hypoxia Inducible Factor 1α (HIF1α) and Sterol Response Element Binding Protein 1c (Srebp1c) transcriptional activity. Based on the hypothesis that mTORC1 integrates the control of T cell metabolism and differentiation via common pathways, our data reveals a dual role for mTORC1/HIF1α in controlling glucose metabolism and CD8 T cell function. Lipid metabolism, controlled by mTORC1/Srebp1c in other cellular systems, has also been linked to T cell differentiation. Preliminary results demonstrate that activated T cells contain active mTORC1/Srebp1c signaling and suggest mTORC1 activity controls Srebp1c target genes, supporting a potential role for mTORC1/Srebp1c in the control of T cell function. This project aims to characterize the role for mTORC1/Srebp1c in the activation, differentiation and function of T lymphocytes using complementary pharmacological and genetic approaches and using state of the art in vivo technologies.
Original text from CORDIS.
Participants
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinCoordinatorIreland
Links
Data: CORDIS, © European Union
